---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-25-000088"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:30:12.111634+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics Q1 net loss widens to $62.9M; ivonescimab gets second China approval

## Summary
- GAAP net loss $62.9M ($0.09/share) vs $43.5M ($0.06) in Q1 2024; R&D expenses rose to $51.2M.
- Cash and investments $361.3M at Mar 31, 2025 vs $412.3M at Dec 31, 2024; non-GAAP op expenses $55.7M.
- Ivonescimab showed statistically significant PFS superiority vs tislelizumab in HARMONi-6 trial (squamous NSCLC).
- China NMPA approved ivonescimab for second indication (1L NSCLC with PD-L1+); interim OS HR=0.777.
- Appointed Robert LaCaze as CCO; enrollment ongoing in HARMONi-3 and HARMONi-7; HARMONi topline expected mid-2025.

## SEC filing metadata
- accession: 0001599298-25-000088
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000088/0001599298-25-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000088/smmt-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-25-000088
- JSON: https://secwatch.observer/filing/0001599298-25-000088.json
- Plain text: https://secwatch.observer/filing/0001599298-25-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.